Antiepileptic drugs during pregnancy: Pharmacokinetics and transplacental transfer

Current Pharmaceutical Biotechnology

Volumn 12, Issue 5, 2011, Pages 781-788

  de Santis, Marco ^a   de Luca, Carmen ^a   Mappa, Ilenia ^a   Cesari, Elena ^a   Quattrocchi, Tomasella ^a   Spagnuolo, Terryann ^a   Visconti, Daniela ^a   Caruso, Alessandro ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Antiepileptic drugs; Epilepsy; Pharmacokinetics; Placenta; Placental transfer; Pregnancy; Teratology

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; VALPROIC ACID;

CONGENITAL MALFORMATION; DEVELOPMENTAL DISORDER; DRUG TRANSPORT; EPILEPSY; HEADACHE; HUMAN; MOOD DISORDER; NEURAL TUBE DEFECT; PLACENTAL TRANSFER; POLYPHARMACY; PREGNANCY; PREGNANT WOMAN; REVIEW;

EID: 79955611400     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111795470958     Document Type: Review

References (92)

1. Harden, C.L.; Meador, K.J.; Pennell, P.B.; Hauser, W.A.; Gronseth, G.S.; French, J.A.; Wiebe, S.; Thurman, D.; Koppel, B.S.; Kaplan, P.W.; Robinson, J.N.; Hopp, J.; Ting, T.Y.; Gidal, B.; Hovinga, C.A.; Wilner, A.N.; Vazquez, B.; Holmes, L.; Krumholz, A.; Finnell, R.; Hirtz, D.; Le Guen, C; American Academy of Neurology; American Epilepsy Society. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia, 2009, 50(5), 1237-1246.
2. Kluger, B.M.; Meador, K.J. Teratogenicity of antiepileptic medications. Semin. Neurol., 2008, 28(3), 328-335.
3. Pennell, P.B. Pregnancy in women who have epilepsy. Neurol. Clin., 2004, 22(4), 799-820.
4. Morrell, M.J. Antiepileptic drug use in women. In: Antiepileptic drugs; Levy, R.; Mattson, R; Meldrum, B; Perucca, E., Eds; Lippincott Williams & Wilkins: Philadelphia, 2002, pp. 132-148.
5. Pennell, P.B. Antiepileptic drugs during pregnancy: what is known and which AEDs seem to be safest? Epilepsia, 2008, 49(suppl. 9), 43-55.
6. Kaplan, P.W.; Norwitz, E.R.; Ben-Menachem, E.; Pennell, P.B.; Druzin, M.; Robinson, J.N.; Gordon, J.C. Obstretic risks for women with epilepsy during pregnancy. Epilepsy Behav., 2007, 11(3), 283-291.
7. Meador, K.J.; Pennell, P.B.; Harden, C.L.; Gordon, J.C.; Tomson, T.; Kaplan, P.W.; Holmes, G.L.; French, J.A.; Hauser, W.A.; Wells, P.G.; Cramer, J.A.; HOPE Work Group. Pregnancy registries in epilepsy: a consensus statement on health outcomes. Neurology, 2008, 71(14), 1109-1117.
8. Thomas S.V. Management of epilepsy and pregnancy. J. Postgrad. Med., 2006, 52(1), 57-64.
9. Cross, J.C. Placental function in development and disease. Reprod. Fertil. Dev., 2006, 18(1-2), 71-76.
10. Syme, M.R.; Paxton, J.W.; Keelan, J.A. Drug transfer and metabolism by the human placenta. Clin. Pharmacokinet., 2004, 43(8), 487-514.
11. Pasanen, M.; Pelkonen, O. The expression and environmental regulation of P450 enzymes in human placenta. Crit. Rev. Toxicol., 1994, 24(3), 211-229.
12. Pasanen, M. The expession and regulation of drug metabolism in human placenta. Adv. Drug Deliv. Rev., 1999, 38(1), 81-97.
13. Marin, J.J.; Briz, O.; Serrano, M.A. A review on the molecular mechanisms involved in the placental barrier for drugs. Curr. Drug Deliv., 2004, 1(3), 275-289.
14. Bourget, P.; Roulot, C.; Fernandez, H. Models for placental transfer studies of drugs. Clin. Pharmacokinet., 1995, 28(2), 161-180.
15. Plonait, S.L.; Nau, H. Physicochemical and structural properties regulating placental drug transfer. In: Fetal and Neonatal Physiology; Polin, R.A.; Fox, W.W.; Abman, S.H., Eds; WB Saunders: Philadelphia, 2004, pp. 197-211.
16. van der Aa, E.M.; Peereboom-Stegeman, J.H.; Noordhoek, J.; Gribnau, F.W.; Russel, F.G. Mechanisms of drug transfer across the human placenta. Pharm. World Sci., 1998, 20(4), 139-148.
17. Ganapathy, V.; Prasad, P.D.; Ganapathy, M.E.; Leibach, F.H. Placental transporters relevant to drug distribution across the maternalfetal interface. J. Pharmacol. Exp. Ther., 2000, 294(2), 413-420.
18. Vähäkangas, K.; Myllynen, P. Drug transporters in the human blood-placental barrier. Br. J. Pharmacol., 2009, 158(3), 665-678.
19. Atkinson, D.E.; Brice-Bennett, S.; D'Souza, S.W. Antiepileptic medication during pregnancy: does fetal genotype affect outcome? Pediatr. Res., 2007, 62(2), 120-127.
20. Atkinson, D.E.; Greenwood, S.L.; Sibley, C.P.; Glazier, J.D.; Fairbairn, L.J. Role of MDR1 and MRP1 in trophoblast cells, elucidated using retroviral gene transfer. Am. J. Physiol. Cell Physiol., 2003, 285(3), C584-C591.
21. St-Pierre, M.V.; Serrano, M.A.; Macias, R.I.; Dubs, U.; Hoechli, M.; Lauper, U.; Meier, P.J.; Marin, J.J. Expression of members of the multidrug resistance protein family in human term placenta. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2000, 279(4), R1495-R1503.
22. Mathias, A.A.; Hitti, J.; Unadkat, J.D. P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2005, 289(4), R963-R969.
23. Sun, M.; Kingdom, J.; Baczyk, D.; Lye, S.J.; Matthews, S.G.; Gibb, W. Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta, 2006, 27(6-7), 602-609.
24. Lankas, G.R.; Wise, L.D.; Cartwright, M.E.; Pippert, T.; Umbenhauer, D.R. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod. Toxicol., 1998, 12(4), 457-463.
25. Smit, J.W.; Huisman, M.T.; van Tellingen, O.; Wiltshire, H.R.; Schinkel, A.H. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J. Clin. Invest., 1999, 104(10), 1441-1447.
26. Yang, C.P.; DePinho, S.G.; Greenberger, L.M.; Arceci, R.J.; Horwitz, S.B. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. J. Biol. Chem., 1989, 264(2), 782-788.
27. Jonker, J.W.; Smit, J.W.; Brinkhuis, R.F.; Maliepaard, M.; Beijnen, J.H.; Schellens, J.H.; Schinkel, A.H. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst., 2000, 92(20), 1651-1656.
28. Tomson, T. Gender aspects of pharmacokinetics of new and old AEDs: pregnancy and breast-feeding. Ther. Drug Monit., 2005, 27(6), 718-721.
29. Sabers, A.; Tomson, T. Managing antiepileptic drugs during pregnancy and lactation. Curr. Opin. Neurol., 2009, 22(2), 157-161.
30. Markovitz, P.J.; Calabrese, J.R. Use of anticonvulsants for manic depression during pregnancy. Psychosomatics, 1990, 31(1), 118.
31. Levy, R.H.; Yerby, M.S. Effects of pregnancy on antiepileptic drug utilization. Epilepsia, 1985, 26(Suppl 1), S52-S57.
32. Yerby, M.; Friel, P.N.; McCormick, K. Antiepileptic drug disposition during pregnancy. Neurology, 1992, 42(4 Suppl 5), 12-16.
33. Philbert, A.; Pedersen, B; Dam, M. Concentration of valproate during pregnancy, in the newborn and in breast milk. Acta Neurol. Scand., 1985, 72(5), 460-463.
34. Lander, C.M.; Smith, M.T.; Chalk, J.B.; de Wytt, C.; Symoniw, P.; Livingstone, I.; Eadie, M.J. Bioavailability and pharmacokinetics of phenytoin during pregnancy. Eur. J. Clin. Pharmacol., 1984, 27(1), 105-110.
35. Freed, C.R.; Gal, J.; Manchester, D.K. Dosage of phenytoin during pregnancy. JAMA, 1985, 253(19), 2833-2834.
36. Dalessio, D.J. Current concepts. Seizure disorders and pregnancy. N. Engl. J. Med., 1985, 312(9), 559-563.
37. Battino, D.; Binelli, S.; Bossi, L.; Como, M.L.; Croci, D.; Cusi, C.; Avanzini, G. Changes in primidone/phenobarbitone ratio during pregnancy and the puerperium. Clin. Pharmacokinet., 1984, 9(3), 252-260.
38. Tomson, T.; Lindbom, U.; Ekqvist, B.; Sundqvist, A. Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin. Epilepsia, 1994, 35(1), 122-130.
39. Nau, H.; Kuhnz, W.; Löscher, W. Effects of pregnancy on seizure threshold and the disposition and efficacy of antiepileptic drugs in the mouse. Life Sci., 1985, 36(7), 663-669.
40. Chou, R.C.; Levy, G. Kinetics of drug action in disease states III: Effect of pregnancy on the relationship between phenytoin concentration and antiseizure activity in rats. J. Pharm. Sci., 1984, 73(10), 1348-1351.
41. Lander, C.M.; Livingstone, I.; Tyrer, J.H.; Eadie, M.J. The clearance of anticonvulsant drugs in pregnancy. Clin. Exp. Neurol., 1981, 17, 71-78.
42. Yerby, M.S.; Friel, P.N.; McCormick, K.; Koerner, M.; Van Allen, M.; Leavitt, A.M.; Sells, C.J.; Yerby, J.A. Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding. Epilepsy Res., 1990, 5(3), 223-228.
43. Mazzucchelli, I.; Onat, F.Y.; Ozkara, C.; Atakli, D.; Specchio, L.M.; Neve, A.L.; Gatti, G.; Perucca, E. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia, 2006, 47(3), 504-509.
44. Christensen, J.; Sabers, A.; Sidenius, P. Oxcarbazepine concentrations during pregnancy: a retrospective study in patients with epilepsy. Neurology, 2006, 67(8), 1497-1499.
45. EURAP Study Group. Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology, 2006, 66(3), 354-360.
46. Reproductive Toxicology Center. http://www.reprotox.org/ Members/ AgentList.aspx?l=E (accessed February 14, 2010).
47. Kuhnz, W.; Koch, S.; Jakob, S.; Hartmann, A.; Helge, H.; Nau, H. Ethosuximide in epileptic women during pregnancy and lactation period. Placental transfer, serum concentrations in nursed infants and clinical status. Br. J. Clin. Pharmacol., 1984, 18(5), 671-677.
48. Brunton, L.L.; Lazo, J.S.; Parker, K.L. Goodman & Gilman' s. The Pharmacological Basis of Therapeutics; 11th ed.; McGraw-Hill: New York, 2005.
49. Maurizis, J.C.; Rapp, M.; Madelmont, J.C.; Gillardin, J.M.; Lepage, F.; Labarre, P.; Dupuy, J.M.; Veyre, A. Disposition of stiripentol in the pregnant and non-pregnant female rat. Xenobiotica, 1993, 23(12), 1335-1343.
50. Ohman, I.; Vitols, S.; Tomson, T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia, 2000, 41(6), 709-713.
51. Tran, T.A.; Leppik, I.E.; Blesi, K.; Sathanandan, S.T.; Remmel, R. Lamotrigine clearance during pregnancy. Neurology, 2002, 59(2), 251-255.
52. de Haan, G.J.; Edelbroek, P.; Segers, J.; Engelsman, M.; Lindhout, D.; Dévilé-Notschaele, M.; Augustijn, P. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology, 2004, 63(3), 571-573.
53. Pennell, P.B.; Newport, D.J.; Stowe, Z.N.; Helmers, S.L.; Montgomery, J.Q.; Henry, T.R. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology, 2004, 62(2), 292-295.
54. Petrenaite, V.; Sabers, A.; Hansen-Schwartz, J. Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res., 2005, 65(3), 185-188.
55. Vajda, F.J.; Hitchcock, A.; Graham, J.; Solinas, C.; O'Brien, T.J.; Lander, C.M.; Eadie, M.J. Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry. Eur. J. Neurol., 2006, 13(6), 645-654.
56. Pennell, P.B.; Koganti, A.; Helmers, S. The impact of pregnancy and childbirth on the elimination of levetiracetam. Epilepsia, 2005, 46(Suppl 8), 89.
57. Tomson, T.; Palm, R.; Källén, K.; Ben-Menachem, E.; Söderfeldt, B.; Danielsson, B.; Johansson, R.; Luef, G.; Ohman, I. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia, 2007,48(6), 1111-1116.
58. Tisch, M.L.; Mushtaq, R. The clinical utility of levetiracetam serum level monitoring during pregnancy. Epilepsia, 2007, 48(Suppl 6), 343-344.
59. Tran, A.; O'Mahoney, T.; Rey, E.; Mai, J.; Mumford, J.P.; Olive, G. Vigabatrin: placental transfer in vivo and excretion into breast milk of the enantiomers. Br. J. Clin. Pharmacol., 1998, 45(4), 409-411.
60. Nau, H.; Kuhnz, W.; Egger, H.J.; Rating, D.; Helge, H. Anticonvulsants during pregnancy and lactation. Transplacental, maternal and neonatal pharmacokinetics. Clin. Pharmacokinet., 1982, 7(6), 508-543.
61. Fowler, D.W.; Eadie, M.J.; Dickinson, R.G. Transplacental transfer and biotransformation studies of valproic acid and its glucuronide(s) in the perfused human placenta. J. Pharmacol. Exp. Ther., 1989, 249(1), 318-323.
62. Nau, H.; Scott, W.J. Jr. Weak acids may act as teratogens by accumulating in the basic milieu of the early mammalian embryo. Nature, 1986, 323(6085), 276-278.
63. Froescher, W.; Gugler, R.; Niesen, M.; Hoffmann, F. Protein binding of valproic acid in maternal and umbilical cord serum. Epilepsia, 1984, 25(2), 244-249.
64. Nau, H.; Rating, D.; Koch, S.; Hauser, I.; Helge, H. Placental transfer and neonatal pharmacokinetics of valproic acid and some of its metabolites. In: Epilepsy, Pregnancy, and the Child; Janz, D.; Dam M.; Richens, A.; Bossi, L.; Helge, H.; Schmidt, D., Eds: Raven Press: New York, 1982, pp. 367-372.
65. Albani, F.; Riva, R.; Contin, M.; Baruzzi, A.; Altomare, M.; Merlini, G.P.; Perucca, E. Differential transplacental binding of valproic acid: influence of free fatty acids. Br. J. Clin. Pharmacol., 1984, 17(6), 759-762.
66. Staud, F.; Fendrich, Z.; Jindrová, O.; Láznícek, M. Phenytoin transfer across the in situ perfused rat term placenta. Pharmazie, 1997, 52(11), 871-874.
67. Shah, Y.G.; Miller, R.K. The pharmacokinetics of phenytoin in perfused human placenta. Pediatr. Pharmacol. (New York), 1985, 5(3), 165-179.
68. Ishizaki, T.; Yokochi, K.; Chiba, K.; Tabuchi, T.; Wagatsuma, T. Placental transfer of anticonvulsants (phenobarbital, phenytoin, valproic acid) and the elimination from neonates. Pediatr. Pharmacol. (New York), 1981, 1(4), 291-303.
69. DeVane, C.L.; Simpkins, J.W.; Stout, S.A. Distribution of phenobarbital and phenytoin in pregnant rats and their fetuses. Epilepsia, 1991, 32(2), 250-256.
70. Wu, S.P.; Shyu, M.K.; Liou, H.H.; Gau, C.S.; Lin, C.J. Interaction between anticonvulsants and human placental carnitine transporter. Epilepsia, 2004, 45(3), 204-210.
71. Winn, L.M.; Wells, P.G. Evidence for Ras-dependent signal transduction in phenytoin teratogenicity. Toxicol. Appl. Pharmacol., 2002, 184(3), 144-152.
72. Wells, P.G.; Henderson, J.T.; Kasapinovic, S.; Laposa, R.R. Reactive oxygen species (ROS) and oxidative damage in teratogenesis. Toxicologist, 2002, 66(S-1), 211.
73. Sit, M.; Chen, C.S.; Wells, P.G. Effects of i.p. maternal vitamin E administration on fetal development and phenytoin embryopathies. Toxicologist, 2003, 72(S-1), 342-343.
74. Wells, P.G.; Bhuller, Y.; Chen, C.S.; Jeng, W.; Kasapinovic, S.; Kennedy, J.C.; Kim, P.M.; Laposa, R.R.; McCallum, G.P.; Nicol, C.J.; Parman, T.; Wiley, M.J.; Wong. A.W. Molecular and biochemical mechanisms in teratogenesis. Toxicol. Appl. Pharmacol., 2004, 197(3), 162-163.
75. Wells, P. G.; Bhuller, Y.; Chen, C. S.; Jeng, W.; Kasapinovic, S.; Kennedy, J. C.; Kim, P. M.; Laposa, R.R.; McCallum, G. P.; Nicol, C. J.; Parman, T.; Wiley, M. J.; Wong. A.W. Molecular and biochemical mechanisms in teratogenesis involving reactive oxygen species. Toxicol. Appl. Pharmacol., 2005, 207(2 Suppl), 354-366.
76. Kluck, R.M.; Cannell, G.R.; Hooper, W.D.; Eadie, M.J.; Dickinson, R.G. Disposition of phenytoin and phenobarbitone in the isolated perfused human placenta. Clin. Exp. Pharmacol. Physiol., 1988, 15(11), 827-836.
77. Pienimäki, P.; Hartikainen, A.L.; Arvela, P.; Partanen, T.; Herva, R.; Pelkonen, O.; Vähäkangas, K. Carbamazepine and its metabolites in human perfused placenta and in maternal and cord blood. Epilepsia, 1995, 36(3), 241-248.
78. Pienimäki, P.; Lampela, E.; Hakkola, J.; Arvela, P; Raunio, H.; Vähäkangas, K. Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta. Epilepsia, 1997, 38(3), 309-316.
79. Pynnönen, S.; Kanto, J.; Sillanpää, M.; Erkkola, R. Carbamazepine: placental transport, tissue concentrations in foetus and newborn, and level in milk. Acta Pharmacol. Toxicol., (Copenh) 1977, 41(3), 244-253.
80. Myllynen, P; Pienimäki, P; Raunio, H.; Vähäkangas, K. Microsomal metabolism of carbamazepine and oxcarbazepine in liver and placenta. Hum. Exp. Toxicol., 1998, 17(12), 668-676.
81. Bülau, P.; Paar, WD.; von Unruh, G.E. Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother. Eur. J. Clin. Pharmacol., 1988, 34(3), 311-313.
82. Myllynen, P.; Pienimäki, P.; Jouppila, P.; Vähäkangas, K. Transplacental passage of oxcarbazepine and its metabolites in vivo. Epilepsia, 2001, 42(11), 1482-1485.
83. Nau, H.; Rating, D; Häuser, I.; Jäger, E.; Koch, S; Helge, H. Placental transfer and pharmacokinetics of primidone and its metabolites phenobarbital, PEMA and hydroxyphenobarbital in neonates and infants of epileptic mothers. Eur. J. Clin. Pharmacol., 1980, 18(1), 31-42.
84. Adusumalli, V.E.; Yang, J.T.; Wong, K.K.; Kucharczyk, N.; Sofia, R.D. Felbamate pharmacokinetics in the rat, rabbit, and dog. Drug Metab. Dispos., 1991, 19(6), 1116-1125.
85. Myllynen, P.K., Pienimäki, P.K.; Vähäkangas, K.H. Transplacental passage of lamotrigine in a human placental perfusion system in vitro and in maternal and cord blood in vivo. Eur. J. Clin. Pharmacol., 2003, 58(10), 677-682.
86. Johannessen, S.I.; Helde, G.; Brodtkorb, E. Levetiracetam concentrations in serum and in breast milk at birth and during lactation. Epilepsia, 2005, 46(5), 775-777.
87. López-Fraile, I.P.; Cid, A.O.; Juste, A.O.; Modrego, P.J. Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications. Epilepsy Behav., 2009, 15(3), 372-375.
88. Ohman, I.; Vitols, S.; Luef, G.; Söderfeldt, B.; Tomson, T. Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations. Epilepsia, 2002, 43(10), 1157-1160.
89. Ohman, I.; Vitols, S.; Tomson, T. Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy? Epilepsia, 2005, 46(10), 1621-1624.
90. Abdulrazzaq, Y.M.; Padmanabhan, B.; Bastaki, S.M.; Ibrahim, A.; Bener, A. Placental transfer of vigabatrin (gamma-vinyl GABA) and its effect on concentration of amino acids in the embryo of TO mice. Teratology, 2001, 63(3), 127-133.
91. Challier, J.C.; Rey, E.; Bintein, T.; Olive, G. Passage of S(+) and R(-) gamma-vinyl-GABA across the human isolated perfused placenta. Br. J. Clin. Pharmacol., 1992, 34(2), 139-143.
92. European Medicines Agency. http://www.ema.europa.eu/ humandocs/ PDFs/EPAR/lyrica/emea-combined-h546it.pdf [accessed February 14, 2010].